Prevalence and predictors of obesity-related cancers among racial/ethnic groups with metabolic syndrome.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
11
2020
accepted:
12
03
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Obesity-related cancer (ORC) is associated with higher amounts of body fat, which could increase the risk of developing cardiovascular disease (CVD). A significant factor associated with CVD is metabolic syndrome (MetS), and MetS prevalence differs by race/ethnicity. The purpose of this study was to compare the prevalence and predictors of ORCs by race/ethnicity among adults (>18) with MetS. This was a retrospective, cross-sectional study using data from the 1999-2014 National Health and Nutrition Examination Survey (NHANES). A chi-square test was performed to determine differences in ORC prevalence between non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic participants with MetS. A multivariate logistic regression was used to evaluate predictors (race, sex, income, insurance, education, marital status, and smoking status) of ORC among adults with MetS. Of the 1,554 adults, the prevalence of ORC was 30.6% among NHWs, 51.3% in NHBs, and 54.1% in Hispanics (p = <0.001). Females were 6.27 times more likely to have an ORC compared to males (95% CI = 4.95-14.11). Compared to NHWs, NHBs were 2.1 times more likely to have an ORC (95% CI = 1.40-3.38); and Hispanics were 2.5 times more likely (95% CI = 1.39-4.77). For every 1-year unit increase in age, the odds of ORC increased by 3% (95% CI = 1.00-1.05). Among NHANES participants with MetS, the prevalence of ORCs was significantly higher in NHBs and Hispanics, females, and older adults with MetS. Future studies, by race/ethnicity, are warranted on mortality risk of persons with MetS and ORC.
Sections du résumé
BACKGROUND
Obesity-related cancer (ORC) is associated with higher amounts of body fat, which could increase the risk of developing cardiovascular disease (CVD). A significant factor associated with CVD is metabolic syndrome (MetS), and MetS prevalence differs by race/ethnicity. The purpose of this study was to compare the prevalence and predictors of ORCs by race/ethnicity among adults (>18) with MetS.
METHODS
This was a retrospective, cross-sectional study using data from the 1999-2014 National Health and Nutrition Examination Survey (NHANES). A chi-square test was performed to determine differences in ORC prevalence between non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic participants with MetS. A multivariate logistic regression was used to evaluate predictors (race, sex, income, insurance, education, marital status, and smoking status) of ORC among adults with MetS.
RESULTS
Of the 1,554 adults, the prevalence of ORC was 30.6% among NHWs, 51.3% in NHBs, and 54.1% in Hispanics (p = <0.001). Females were 6.27 times more likely to have an ORC compared to males (95% CI = 4.95-14.11). Compared to NHWs, NHBs were 2.1 times more likely to have an ORC (95% CI = 1.40-3.38); and Hispanics were 2.5 times more likely (95% CI = 1.39-4.77). For every 1-year unit increase in age, the odds of ORC increased by 3% (95% CI = 1.00-1.05).
CONCLUSIONS
Among NHANES participants with MetS, the prevalence of ORCs was significantly higher in NHBs and Hispanics, females, and older adults with MetS. Future studies, by race/ethnicity, are warranted on mortality risk of persons with MetS and ORC.
Identifiants
pubmed: 33826671
doi: 10.1371/journal.pone.0249188
pii: PONE-D-20-37144
pmc: PMC8026066
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249188Subventions
Organisme : NHLBI NIH HHS
ID : R25 HL126145
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cells. 2020 May 08;9(5):
pubmed: 32397183
Pediatr Clin North Am. 2015 Oct;62(5):1227-40
pubmed: 26318949
Int J Cancer. 2014 Oct 1;135(7):1673-86
pubmed: 24615287
Br J Sports Med. 2008 Aug;42(8):636-47
pubmed: 18487249
Am J Epidemiol. 2020 Feb 28;189(2):108-115
pubmed: 31602476
Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):591-598
pubmed: 31915146
Vital Health Stat 1. 1994 Jul;(32):1-407
pubmed: 7975354
Value Health. 2019 Dec;22(12):1378-1386
pubmed: 31806194
Eur J Oncol Nurs. 2012 Sep;16(4):399-405
pubmed: 22000813
Int J Epidemiol. 2012 Dec;41(6):1706-18
pubmed: 23148106
Int J Obes (Lond). 2020 Mar;44(3):601-608
pubmed: 31974408
Lancet Oncol. 2010 Feb;11(2):193-203
pubmed: 20152771
Sci Rep. 2019 Feb 7;9(1):1546
pubmed: 30733504
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
J Cancer Educ. 2008;23(4):201-3
pubmed: 19058065
Public Health Nutr. 2018 Jun;21(9):1618-1626
pubmed: 29463332
PLoS One. 2015 Mar 24;10(3):e0119313
pubmed: 25803438
Lancet Oncol. 2002 Sep;3(9):565-74
pubmed: 12217794
Eur J Cancer. 2012 Sep;48(14):2137-45
pubmed: 22446023
MMWR Morb Mortal Wkly Rep. 2017 Oct 03;66(39):1052-1058
pubmed: 28981482
Du Bois Rev. 2011 Apr;8(1):115-132
pubmed: 25632292
Cancer Causes Control. 2001 Jan;12(1):13-21
pubmed: 11227921
Prev Chronic Dis. 2017 Mar 16;14:E24
pubmed: 28301314
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1395-408
pubmed: 23697611
J Clin Oncol. 2016 Sep 10;34(26):3133-40
pubmed: 27458295
Crit Rev Oncol Hematol. 2016 Dec;108:128-136
pubmed: 27931830